ReviewFrontiers in pediatrics2022
Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology.
Review in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Unmasking Incontinentia Pigmenti: A Multimodal Clinico-Dermoscopic and Pathologic Correlation.Diagnostics (Basel, Switzerland) · 2026Article
- Consensus Guidance for Screening, Classification, and Treatment of Retinopathy Associated with Incontinentia Pigmenti.Ophthalmology science · 2026Article
- Single-Cell RNA Sequencing in Incontinentia Pigmenti With Neonatal Encephalopathy Reveals Broad Immune Activation Moderated by Steroids.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Article
- Partial Loss of NEMO Function in a Female Carrier with No Incontinentia Pigmenti.Journal of clinical medicine · 2025Article
- Incorporating Nanopore Sequencing Into a Diverse Diagnostic Toolkit for Incontinentia Pigmenti.Human mutation · 2025Article
- Enterokinase deficiency associated with novel TMPRSS15 gene mutations: a case report.Frontiers in pediatrics · 2025Article
- Prevalence and clinical characteristics of incontinentia pigmenti: a nationwide population-based study.Orphanet journal of rare diseases · 2024Article
- Bioinformatic Analysis ofInternational journal of molecular sciences · 2024Article
- NF-κB Activation and X-Inactivation in Females with Incontinentia Pigmenti and Recurrent Infections.Journal of clinical immunology · 2024Article
- Central nervous system anomalies in 41 Chinese children incontinentia pigmenti.BMC neuroscience · 2024Article
- Case report: Variability in clinical manifestations within a family with incontinentia pigmenti.Frontiers in medicine · 2024Article
- NovelFrontiers in medicine · 2023Article
- Incontinentia Pigmenti: A Case Report of Early Clinical Symptoms in a Lack of Family Inheritance Positive Result.Clinical, cosmetic and investigational dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incontinentia pigmenti (IP) is an X-linked dominant genodermatosis. The disease is known to be caused by recurrent deletion of exons 4-10 of the Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.